Skip to main content
SpringerLink
Log in

Treatment of patients with familial defective apolipoprotein B-100 with pravastatin and gemfibrozil: a two-period cross-over study

  • Clinical Pharmacology
  • Published:
The clinical investigator Aims and scope Submit manuscript

Abstract

Thirty patients with familial defective apolipoprotein B-100 were treated in a two-period (8 weeks each) cross-over study with pravastatin and gemfibrozil. Cholesterol, LDL cholesterol, and apo B were reduced by 20–25% (P < 10−4) by pravastatin and by 4–6% by gemfibrozil (pravastatin vs. gemfibrozil:P < 10−4). Response to pravastatin was variable and not correlated to gender, age, or apo E genotype. Gemfibrozil lowered triglycerides by 25% (P < 10−4) and raised HDL cholesterol by 11%. The effects of pravastatin on these two interrelated variables were significantly smaller. Both drugs increased Lp(a) significantly by about 10%. The LDL cholesterol lowering effect of pravastatin in patients with FDB is similar to that observed in patients with familial hypercholesterolemia.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Abbreviations

FDB:

familial defective apolipoprotein B-100

LDL:

low density lipoprotein

VLDL:

very low density lipoprotein

HDL:

high density lipoprotein

LDL-R:

low density lipoprotein receptor

HMG CoA:

β-hydroxy-β-methyl-glutaryl coenzyme A

FH:

familial hypercholesterolemia

TG:

triglycerides

apo B:

apolipoprotein B-100

apo Al:

apolipoprotein Al

apo E:

apolipoprotein E

Lp(a):

lipoprotein(a)

PCR:

polymerase chain reaction

References

  1. Arad Y, Ramakrishnan R, Ginsberg HN (1990) Lovastatin therapy reduces low density lipoprotein apo B levels in subjects with combined hyperlipidemia by reducing the production of apo B-containing lipoproteins: implications for the pathophysiology of apo B production. J Lipid Res 31:567–582

    Google Scholar 

  2. Armitage P, Berry G (1987) Statistical methods in medical research, 2nd edn. Blackwell Scientific Publications, Oxford, pp 222–226

    Google Scholar 

  3. Bilheimer DW, Grundy SM, Brown MS, Goldstein JL (1983) Mevinolin and colestipol stimulate receptor-mediated clearance of low density lipoproteins from plasma in familial hypercholesterolemia heterozygotes. Proc Natl Acad Sci USA 80:4124–4128

    Google Scholar 

  4. Bimmermann A, Boerschmann C, Schwartzkopff W, Von Baeyer H, Schleicher J (1991) Effective therapeutic measures for reducing lipoprotein (a) dyslipidemia. Lipoprotein (a) reduction with sustained-release bezafibrate. Curr Ther Res Clin Exp 49:635–643

    Google Scholar 

  5. Carmena R, Roederer G, Mailloux H, Lussier-Cacan S, Davignon J (1993) The response to lovastatin treatment in patients with heterozygous familial hypercholesterolemia is modulated by apolipoprotein E polymorphism. Metabolism 42:895–901

    Google Scholar 

  6. Coresh J, Kwiterowich PO, Smith HH, Bachorik PS (1993) Association of plasma triglyceride concentration and LDL particle diameter, density, and chemical composition with premature coronary artery disease in men and women. J Lipid Res 34:1687–1697

    Google Scholar 

  7. Endo A (1992) The discovery and development of HMG-CoA reductase inhibitors. J Lipid Res 33:1569–1582

    Google Scholar 

  8. Farmer JA, Washington LC, Jones PH, Shapiro DR, Gotto AM Jr, Mantell G (1992) Comparative effects of simvastatin and lovastatin in patients with hypercholesterolemia. Clin Ther 14:708–717

    Google Scholar 

  9. Friedewald WT, Levy RI, Fredrickson DS (1972) Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18:499–502

    Google Scholar 

  10. Hansen PS, Rüdiger N, Tybjærg-Hansen A, Færgeman O, Gregersen N (1991) Detection of the apoB-3500 mutation by gene amplification and cleavage with MspI. J Lipid Res 32:1229–1233

    Google Scholar 

  11. Hansen PS, Meinertz H, Jensen HK, Fruergaard P, Launbjerg J, Klausen IC, Lemming L, Gerdes LU, Gregersen N, Faergeman O (1994) Characteristics of 46 heterozygous carriers and 57 unaffected relatives in five Danish families with familial defective apolipoprotein B-100. Arterioscler Thromb 14:207–213

    Google Scholar 

  12. Hills M, Armitage P (1979) The two-period cross-over clinical trial. Br J Clin Pharmacol 8:7–20

    Google Scholar 

  13. Hixson JE, Vernier DT (1990) Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with Hhal. J Lipid Res 31:545–548

    Google Scholar 

  14. Illingworth DR, Vakar F, Mahley RW, Weisgraber KH (1992) Hypocholesterolemic effects of lovastatin in familial defective apolipoprotein B-100. Lancet 339:598–600

    Google Scholar 

  15. Innerarity TL, Mahley RW, Weisgraber KH, Bersot TP, Krauss RM, Vega GL, Grundy SM, Friedl W, Davignon J, McCarthy BJ (1990) Familial defective apolipoprotein B-100: a mutation of apolipoprotein B that causes hypercholesterolemia. J Lipid Res 31:1337–1350

    Google Scholar 

  16. Klausen IC, Gerdes LU, Schmidt EB, Dyerberg J, Færgeman O (1992) Differences in apolipoprotein(a) polymorphism in West Greenland Eskimos and Caucasian Danes. Hum Genet 89:384–388

    Google Scholar 

  17. Klausen IC, Gerdes LU, Meinertz H, Hansen FA, Faergeman O (1993) Apolipoprotein(a) polymorphism predicts the increase of Lp(a) by pravastatin in patients with familial hypercholesterolemia treated with bile acid sequestration. Eur J Clin Invest 23:240–245

    Google Scholar 

  18. Klienman Y, Schonfeld G, Gavish D, Oschry Y, Eisenberg S (1987) Hypolipidemic therapy modulates expression of apolipoprotein B epitopes on low density lipoproteins. Studies in mild to moderate hypertriglyceridemic patients. J Lipid Res 28:540–548

    Google Scholar 

  19. Larsen ML, Illingworth DR (1994) Drug treatment of dyslipoproteinemia. Med Clin North Am 78:225–245

    Google Scholar 

  20. Leren TP, Hjermann I, Foss OP, Leren P, Berg K (1992) Long-term effect of lovastatin alone and in combination with cholestyramine on lipoprotein(a) level in familial hypercholesterolemic subjects. Clin Investig 70:711–718

    Google Scholar 

  21. The Lovastatin Pravastatin Study Group (1993) A multicenter comparative trial of lovastatin and pravastatin in the treatment of hypercholesterolemia. Am J Cardiol 71:810–815

    Google Scholar 

  22. Maher VMG, Gallagher JJ, Thompson GR, Myant NB (1991) Response to cholesterol-lowering drugs in familial defective apolipoprotein B-100. Atherosclerosis 91:73–76

    Google Scholar 

  23. Miettinen TA (1991) Inhibition of cholesterol absorption by HMG-CoA reductase inhibitor. Eur J Clin Pharmacol 40 [Suppl 1]:S19-S21

    Google Scholar 

  24. Nozaki S, Vega GL, Haddox RJ, Dolan ET, Grundy SM (1990) Influence of lovastatin on concentrations and compositions of lipoprotein subfractions. Atherosclerosis 84:101–110

    Google Scholar 

  25. O'Malley JP, Illingworth DR (1990) The influence of apolipoprotein E phenotype on the response to lovastatin treatment in patients with heterozygous familial hypercholesterolemia. Metabolism 39:150–154

    Google Scholar 

  26. Rauh G, Keller C, Kormann B, Spengel F, Schuster H, Wolfram G, Zöllner N (1992) Familial defective apolipoprotein B-100: clinical characteristics of 54 cases. Atherosclerosis 92:233–241

    Google Scholar 

  27. Schmidt EB, Illingworth DR, Bacon S, Mahley RW, Weisgraber KH (1993) Hypocholesterolemic effects of cholestyramine and colestipol in patients with familial defective apolipoprotein B-100. Atherosclerosis 98:213–217

    Google Scholar 

  28. Schmidt EB, Illingworth DR, Bacon S, Russell SJ, Thatcher SR, Mahley RW, Weisgraber KH (1993) Hypolipidemic effects of nicotinic acid in patients with familial defective apolipoprotein B-100. Metabolism 42:137–139

    Google Scholar 

  29. Schuster H, Rauh G, Kormann B, Hepp T, Humphries S, Keller K, Wolfram G, Zøllner N (1990) Familial defective apolipoprotein B-100. Comparison with familial hypercholesterolemia in 18 cases detected in Münich. Arteriosclerosis 4:577–581

    Google Scholar 

  30. Slunga L, Johnson O, Dahlén GH (1992) Changes in Lp(a) lipoprotein levels during the treatment of hypercholesterolemia with simvastatin. Eur J Clin Pharmacol 43:369–373

    Google Scholar 

  31. Soria LF, Ludwig EH, Clarke HRG, Vega GL, Grundy SM, McCarthy BJ (1989) Association between a specific apolipoprotein B mutation and familial defective apolipoprotein B-100. Proc Natl Acad Sci USA 86:587–591

    Google Scholar 

  32. Tikkanen MJ (1992) Fibric acid derivatives. Curr Opin Lipidol 3:29–33

    Google Scholar 

  33. Tilly-Kiesi M, Tikkanen MJ (1991) Low density lipoprotein density and composition in hypercholesterolaemic men treated with HMG CoA reductase inhibitors and gemfibrozil. J Int Med 229:427–434

    Google Scholar 

  34. Tybjaerg-Hansen A, Humphries S (1992) Familial defective apolipoprotein B-100: a single mutation that causes hypercholesterolemia and premature coronary artery disease. Atherosclerosis 96:91–107

    Google Scholar 

  35. Utermann G, Menzel HJ, Kraft HG, Duba HC, Kemmler HG, Seitz C (1987) Lp(a) glycoprotein phenotypes: Inheritance and relation to Lp(a)-lipoprotein concentrations in plasma. J Clin Invest 80:458–465

    Google Scholar 

  36. Yuan J, Tsai MY, Hegland J, Hunninghake DB (1991) Effects of fluvastatin (XU 62-320), an HMG-CoA Reductase inhibitor, on the distribution and composition of low density lipoprotein subspecies in humans. Atherosclerosis 87:147–157

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Internal Medicine and Cardiology A, Aarhus Amtssygehus University Hospital, Tage-Hansensgade 2, DK-8000, Aarhus C, Denmark

    P. S. Hansen, L. U. Gerdes, I. C. Klausen & O. Faergeman

  2. Department of Medicine B, Rigshospitalet, Copenhagen, Denmark

    H. Meinertz

Authors
  1. P. S. Hansen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. H. Meinertz
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. L. U. Gerdes
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. I. C. Klausen
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. O. Faergeman
    View author publications

    You can also search for this author in PubMed Google Scholar

Additional information

Correspondence to: P.S. Hansen

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hansen, P.S., Meinertz, H., Gerdes, L.U. et al. Treatment of patients with familial defective apolipoprotein B-100 with pravastatin and gemfibrozil: a two-period cross-over study. Clin Investig 72, 1065–1070 (1994). https://doi.org/10.1007/BF00577757

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00577757

Key words

Search

Navigation